On May 8, 2025, Guggenheim analyst Michael Schmidt maintained a "Buy" rating for Revolution Medicines (RVMD, Financial), while lowering the price target from $87.00 to $80.00. This represents an 8.05% decrease from the previous price target.
The adjustment in the price target reflects the analyst's reassessment of the company's future potential, although Guggenheim's confidence in RVMD's investment prospects remains strong, as evidenced by the continued "Buy" rating.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Revolution Medicines Inc (RVMD, Financial) is $72.55 with a high estimate of $88.00 and a low estimate of $57.00. The average target implies an upside of 71.02% from the current price of $42.42. More detailed estimate data can be found on the Revolution Medicines Inc (RVMD) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Revolution Medicines Inc's (RVMD, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Revolution Medicines Inc (RVMD, Financial) in one year is $0.35, suggesting a downside of 99.17% from the current price of $42.42. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Revolution Medicines Inc (RVMD) Summary page.
